Newsroom

Press Releases

01/05/2012 : Yaupon Changes Name to Ceptaris Therapeutics, Inc.

Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today it has changed its name to Ceptaris Therapeutics, Inc., effective immediately. The new name is intended to reflect the recent changes in management and the Company’s ongoing transformation into a commercial organization. Ceptaris Therapeutics’ lead drug candidate, mechlorethamine gel, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell Lymphoma (CTCL).

08/18/2011 : Judy Jones Transitions to President Emeritus of Cutaneous Lymphoma Foundation

After nearly 14 years of passionate service to patients and others affected by cutaneous lymphoma, Judy Jones, Founder of the Cutaneous Lymphoma Foundation (CLF), has stepped away from daily operations and from her role as President of the Board of Directors.

07/28/2011 : Yaupon Therapeutics, Inc. Submits New Drug Application For Proprietaty Gel Formulation Of Mechlorethamine Hydrochloride

Requesting U.S. marketing approval for the topical treatment of early stage (stages I-IIA) mycosis fungoides, a common type of Cutaneous T-Cell Lymphoma

06/16/2011 : FDA Grants Accelerated Approval of Istodax®

FDA Grants Accelerated Approval of Istodax® As Treatment For Patients With Peripheral T-Cell Lymphoma Who Have Received At Least One Prior Therapy

06/01/2011 : Cutaneous Lymphoma Foundation CEO, Jennifer Viano, Talks with OncUView.tv at the American Society of Clinical Oncology's Annual Meeting

Cutaneous Lymphoma Foundation CEO, Jennifer Viano, Talks with OncUView.tv at the American Society of Clinical Oncology’s Annual Meeting

03/11/2011 : Cutaneous Lymphoma Foundation Featured in USA Today

Judy Jones, President Emeritus of the Cutaneous Lymphoma Foundation and President of the Coalition of Skin Diseases, writes about the burden of skin disease in USA Today

02/04/2011 : TenX Biopharma Licenses Zanolimumab From Genmab

01/14/2011 : Celegene Provides Update on Regulatory Submissions

01/03/2011 : Doctors knew how to treat my cancer, but it took years to control my itching

12/08/2010 : Kyowa Hakko Kirin Announces Results from US Phase 1/2 Clinical Trial of KW-0761 (Anti-CCR4 Humanized Monoclonal Antibody) in Patients with Cutaneous T-cell Lymphoma